ClinicalTrials.gg

Program

SAR402663

A development code.

In Sanofi's pipeline, sFLT01 AAV gene therapy. Its studies are mostly in Macular Degeneration, led by Sanofi.

Furthest: phase 2, since Oct 25, 20241 company-led study, 1 open or runningNext primary completion: May 18, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi11 open or runningphase 2since Oct 25, 2024Oct 25, 2024May 18, 2027phase 2 · NCT06660667
  • Named in Sanofi’s own pipeline as SAR402663, phase 2, as of Sep 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 25, 2024First study: phase 2 study in Neovascular Age-related Macular DegenerationFirst studyNCT06660667 · 66 enrolled · United States, United Kingdom

Ahead

  1. May 18, 2027Primary completion: phase 2 study in Neovascular Age-related Macular DegenerationNCT06660667

TargetBeta

“sFLT01 AAV gene therapy”the company's pipeline, read by Claude · source

Other programs on FLT1

ProgramCompanyFurthest phaseStudies
lenvatinibruleEisaiphase 481
nintedanibruleBoehringer Ingelheimphase 476
regorafenibruleBayerphase 440
AxitinibrulePfizerphase 345
chiauranibruleChipscreen Biosciencesphase 315

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06660667Neovascular Age-related Macular Degeneration · United States, United Kingdom2Active, not recruitingMay 18, 202766

How it is read

Names in the registry

  • “SAR402663”, 1 entry

Codes read as this program: SAR402663.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.